Table 3.

Effect of lithium-associated downregulation of CRMP1 and GSK3β and changes in mood severity following 6 weeks of treatment

	YMRS			MADRS
	β	95% CI	P	β	95% CI	P
GSK3β (N = 15)
Unadjusted	2.19	−0.09–4.28	<0.05	−0.61	−3.11–1.88	<0.70
Adjusteda	2.43	−0.44–4.41	<0.02	−0.35	−2.92–2.21	<0.80
CRMP1 (N = 13)
Unadjusted	0.37	0.06–0.68	<0.02	0.42	0.03–0.80	<0.04
Adjusteda	0.36	0.06–0.67	<0.02	0.46	0.08–0.84	<0.02
Unadjustedb	0.54	0.15–0.94	<0.007	0.47	−0.06–1.00	<0.08
Adjusteda,b	0.51	0.15–0.88	<0.006	0.52	0.02–1.02	<0.05

^aAdjusted for differences in age, sex, and education

^bAnalysis excluded data from two BD subjects with undetected CRMP1 mRNA levels